FET PET in Differentiating Tumour Progression From Pseudoprogression in High Grade Glioma
ConditionGlioma, Malignant
Trial statusRecruiting
Trial phasePhase 2
Trial typeInterventional
Biological sexAll
Age21+
SponsorSingapore General Hospital
About this trial
The goal of this clinical trial is to evaluate the performance characteristics of O-(2-\[18F\]fluoroethyl)-L-tyrosine (FET) PET in differentiating pseudoprogression from tumour progression in patients with equivocal conventional imaging and determine the sensitivity and specificity of \[18F\]FET-PET in delineating disease. The main question\[s\] it aims to answer are:
* whether 18F-FET-PET will demonstrate high diagnostic accuracy to detect true tumour progression * whether we can optimise the threshold cut-offs for TBRmax and other relevant parameters in discriminating pseudoprogression and disease progression Participants will undergo a limited 18F-FET PET/CT of the brain in SGH.
Eligibility criteria
Qualifiers
Men or Women, aged 21 years or older at time of screening
Histologically confirmed diagnosis of malignant glioma (defined as WHO grade III or IV) with previous RT to tumour
With enlarging contrast-enhancing and/or T2W/FLAIR-hyperintense lesion(s) on MRI within the previous RT field
Gliomas with Isocitrate dehydrogenase (IDH) wild-type status, as defined on immunohistochemistry
Disqualifiers
Low-grade gliomas (histology grade 1 or 2 by WHO classification)16,17
Previous bevacizumab or other vascular endothelial growth factor (VEGF) targeting agents or anti-angiogenic treatments.
Proven cerebral metastases
IDH-mutated gliomas
Trial design
Treatments tested in this trial
- FET PET
Treatment groups
22 Participants
are divided into 1 treatment groupSponsors and collaborators
Singapore General Hospital
Lead sponsor
National Cancer Centre, Singapore
Collaborator
National Neuroscience Institute Singapore
Collaborator
Duke-NUS Graduate Medical School
Collaborator
Source ClinicalTrials.gov